



Press release

STADA and Sanofi strike consumer healthcare distribution agreement in selected countries in Europe

- Sanofi will distribute its consumer healthcare portfolio through STADA in 20 countries across Europe, including the Nordic countries, the Netherlands, Ireland, Bulgaria and the Baltic States, as well as Balkan and Adriatic countries
- The distribution deal demonstrates STADA's go-to-partner status for healthcare in Europe by strengthening its consumer healthcare portfolio with several attractive brands
- The agreement covering 20 countries comes shortly after STADA agreed to acquire from Sanofi 16 consumer healthcare brands in European countries such as France, Germany, Italy, Poland and Spain

Bad Vilbel, Germany. 27 July 2021 – STADA and Sanofi have entered into a distribution agreement whereby STADA will distribute and market Sanofi's portfolio of well-established consumer healthcare brands, scheduled to start from November 2021, in 20 countries across Europe. Countries covered by the agreement include the Nordic countries Denmark, Finland, Iceland, Norway and Sweden, as well as the Netherlands, Ireland, Malta and Bulgaria. Also included are the Baltic States Estonia, Latvia and Lithuania, plus Albania, Bosnia and Herzegovina, Croatia, Kosovo, Macedonia, Montenegro, Serbia and Slovenia in the Balkans and Adriatic region.

The agreement covers approximately 50 well-established consumer healthcare brands currently marketed by Sanofi in these territories. These include Allegra, Bisolvon, Dulcolax and Essentiale Forte N in therapeutic categories such as allergy, cough & cold, dermatology and digestive health, as well as pain relief and vitamins, minerals and supplements.

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Simone Berger / Miguel Pagan Fernandez
Supervisory Board Chairman: Dr. Günter von Au



STADA will distribute these brands in the 20 markets covered by the distribution deal, leveraging its strong commercial footprint in these countries.

The distribution agreement comes shortly after the announcement of a separate transaction whereby STADA is acquiring 16 well-established brands from Sanofi in European countries such as France, Germany, Italy, Poland and Spain¹.

Explaining the appeal of the latest agreement with STADA, Sanofi's Head of Consumer Healthcare GBU for Europe, Paul Martingell, explained: "This long-term, strategic agreement is another important step on our Sanofi Consumer Healthcare journey, under our strategic pillar of 'cutting & embracing complexity'; allowing us to further increase focus in our Must Win and Stronghold geographies and brands.

For the countries under this agreement, we are delighted that the commercial reach and footprint of STADA will allow us to continue to build even stronger brands and ensure access to our trusted portfolio of brands to consumers and are confident that this collaboration will be a win-win for both our companies and the health and wellness of consumers in these markets."

STADA's Global Head of Consumer Healthcare, Volker Sydow, commented: "This broad marketing and distribution agreement with Sanofi serves as further evidence that STADA is increasingly a go-to-partner for consumer healthcare in Europe. With STADA's strategic consumer healthcare focus on local hero brands, we are confident that we can provide the right level of support, commitment and agility to grow these brands to the next level."

"STADA's strategy has consumer healthcare playing a central role alongside prescription generics and specialty pharmaceuticals," Sydow explained. "STADA is

¹ [Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA - Sanofi; STADA further grows European Consumer Healthcare portfolio | STADA](#)

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Simone Berger / Miguel Pagan Fernandez
Supervisory Board Chairman: Dr. Günter von Au



already a top-five consumer healthcare player in Europe by sales. And we are strengthening our position through a combination of organic expansion through line extensions and brand launches in additional markets, as well as inorganic business-development deals such as the recent acquisitions of Walmark and a portfolio of selected consumer healthcare brands from GlaxoSmithKline last year.”

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2020, STADA achieved group sales of EUR 3,010.3 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 713.3 million. As of 31 December 2020, STADA employed 12,301 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de
Or visit us on the Internet at www.stada.com/investor-relations